Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EPS (Weighted Average and Diluted) (2022 - 2025)

Taysha Gene Therapies' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.09 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 10.0% year-over-year to -$0.09; the TTM value through Sep 2025 reached -$0.33, down 152.38%, while the annual FY2024 figure was -$0.36, 62.5% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.09 at Taysha Gene Therapies, roughly flat from -$0.09 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.92 in Q4 2023 and bottomed at -$1.32 in Q1 2022.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.1 (2024), against an average of -$0.34.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 191.09% in 2023 before it tumbled 107.61% in 2024.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.01 in 2022, then skyrocketed by 191.09% to $0.92 in 2023, then crashed by 107.61% to -$0.07 in 2024, then decreased by 28.57% to -$0.09 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's EPS (Weighted Average and Diluted) are -$0.09 (Q3 2025), -$0.09 (Q2 2025), and -$0.08 (Q1 2025).